Betoptic: Advanced Ophthalmic Solution for Effective Glaucoma Management
| Product dosage: 5ml | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 3 | $11.47 | $34.40 (0%) | 🛒 Add to cart |
| 4 | $10.32 | $45.87 $41.28 (10%) | 🛒 Add to cart |
| 5 | $9.46 | $57.33 $47.30 (18%) | 🛒 Add to cart |
| 6 | $9.32 | $68.80 $55.90 (19%) | 🛒 Add to cart |
| 7 | $8.97 | $80.27 $62.78 (22%) | 🛒 Add to cart |
| 8 | $8.81 | $91.73 $70.52 (23%) | 🛒 Add to cart |
| 9 | $8.60 | $103.20 $77.40 (25%) | 🛒 Add to cart |
| 10 | $8.43
Best per bottle | $114.67 $84.28 (26%) | 🛒 Add to cart |
Synonyms | |||
Betoptic (betaxolol hydrochloride ophthalmic solution) is a topical beta-adrenergic blocking agent specifically formulated for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension. As a cardioselective beta-1 blocker, it offers a favorable safety profile while effectively lowering IOP through reduced aqueous humor production. Its formulation ensures targeted ocular action with minimal systemic absorption, making it a cornerstone in long-term glaucoma therapy protocols. Clinicians value Betoptic for its dual mechanism of efficacy and safety, particularly in patients with reactive airway disease or other contraindications to non-selective beta blockers.
Features
- Contains betaxolol hydrochloride 0.5% as the active pharmaceutical ingredient
- Available as a sterile, isotonic, buffered aqueous solution
- Preserved with benzalkonium chloride 0.01%
- pH adjusted to approximately 7.4 with hydrochloric acid and/or sodium hydroxide
- Supplied in 5mL, 10mL, and 15mL opaque plastic dropper bottles
- Requires storage at controlled room temperature (15°-30°C/59°-86°F)
Benefits
- Effectively reduces intraocular pressure by 20-25% through decreased aqueous production
- Demonstrates cardioselectivity with minimal effect on pulmonary function parameters
- Maintains ocular perfusion pressure and potentially offers neuroprotective benefits
- Provides 12-hour duration of action with twice-daily dosing convenience
- Shows excellent corneal penetration with minimal systemic side effects
- Compatible with most adjunctive glaucoma therapies for combination treatment regimens
Common use
Betoptic is primarily indicated for the chronic management of elevated intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension. It is frequently prescribed as first-line monotherapy or as part of combination therapy when additional IOP reduction is required. The solution is particularly valuable for patients who cannot tolerate non-selective beta blockers due to respiratory comorbidities such as asthma or chronic obstructive pulmonary disease. Ophthalmologists may also consider Betoptic for patients who experience systemic side effects with other classes of glaucoma medications while requiring maintained cardiovascular selectivity.
Dosage and direction
The recommended dosage is one drop of Betoptic 0.5% in the affected eye(s) twice daily. Patients should be instructed to tilt their head backward, look upward, and gently pull down the lower eyelid to create a pouch. After instilling the drop, patients should close their eyes gently and apply digital pressure to the lacrimal sac for 1-2 minutes to minimize systemic absorption. If using other topical ophthalmic medications, patients should wait at least 5 minutes between applications. The solution should be shaken well before each use to ensure proper dispersion of the active ingredient.
Precautions
Patients should be advised that Betoptic may cause temporary blurred vision or other visual disturbances following instillation. Those wearing soft contact lenses should remove them before administration and wait at least 15 minutes before reinsertion due to benzalkonium chloride preservation. Systemic absorption may occur despite topical administration, particularly in patients with corneal damage or those not performing nasolacrimal occlusion. Ophthalmologists should exercise caution when prescribing to patients with diabetes mellitus, as beta blockers may mask signs and symptoms of acute hypoglycemia. Regular monitoring of intraocular pressure and periodic ophthalmologic examinations are recommended during long-term therapy.
Contraindications
Betoptic is contraindicated in patients with known hypersensitivity to any component of the formulation. It should not be used in patients with sinus bradycardia, greater than first-degree atrioventricular block, cardiogenic shock, overt cardiac failure, or history of bronchospasm requiring treatment. The solution is contraindicated in patients with untreated closed-angle glaucoma, as it does not address the underlying mechanical obstruction. Additionally, it should be avoided in patients receiving concomitant therapy with other systemic beta-adrenergic blocking agents due to potential additive effects.
Possible side effects
Ocular adverse reactions occur in approximately 25% of patients and most commonly include transient burning and stinging upon instillation (15%), blurred vision (5%), and foreign body sensation (3%). Less frequent ocular effects include photophobia, itching, dryness, tearing, and conjunctival hyperemia. Systemic side effects, though uncommon due to limited absorption, may include bradycardia, hypotension, bronchospasm, headache, dizziness, and depression. Approximately 1% of patients may experience allergic reactions manifested as eyelid dermatitis, conjunctival erythema, or corneal punctate staining. Rare cases of keratitis, blepharoconjunctivitis, and corneal anesthesia have been reported.
Drug interaction
Concomitant use with oral beta-adrenergic blocking agents may produce additive systemic beta-blockade effects. Caution is advised when administering with calcium channel blockers, digitalis, or antiarrhythmic agents due to potential additive effects on cardiac conduction. Betoptic may antagonize the effects of adrenergic agonists and theophylline. Concurrent use with reserpine or catecholamine-depleting drugs may produce additive effects and hypotension. The solution may enhance the hypoglycemic effect of insulin and oral hypoglycemic agents while masking tachycardia as a sign of hypoglycemia. Anesthetic agents that depress myocardial function may have additive effects when used with betaxolol.
Missed dose
If a dose is missed, patients should instill the drop as soon as they remember, unless it is nearly time for the next scheduled dose. In such cases, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never instil double drops to make up for a missed dose. Consistency in dosing is important for maintaining stable intraocular pressure control, but occasional missed doses are unlikely to cause significant pressure spikes if the overall regimen is maintained. Patients should be educated about the importance of adherence while understanding that single missed doses do not warrant panic or overcompensation.
Overdose
Systemic overdose following ocular administration is unlikely but possible, particularly in elderly patients or those with compromised corneal integrity. Symptoms may include bradycardia, hypotension, bronchospasm, acute cardiac failure, and hypoglycemia. Management should include discontinuation of therapy, supportive measures, and appropriate symptomatic treatment. Atropine may be administered for bradycardia, while bronchodilators may be necessary for bronchospasm. Cardiac failure should be treated with digitalis, diuretics, and oxygen. Hemodialysis is unlikely to be effective due to betaxolol’s protein binding characteristics. Patients should be monitored in a clinical setting until cardiovascular and respiratory parameters stabilize.
Storage
Betoptic should be stored at controlled room temperature between 15°-30°C (59°-86°F). The solution must be protected from light and excessive heat, and the bottle should be kept tightly closed when not in use. Patients should be advised not to freeze the medication and to avoid storing it in bathrooms where moisture and temperature fluctuations may affect stability. The solution should be discarded 28 days after opening, even if some medication remains, to prevent contamination and ensure efficacy. The bottle should not be touched to any surface, including the eye, to maintain sterility.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Betoptic is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not adjust their dosage or discontinue treatment without consulting their ophthalmologist. While every effort has been made to ensure accuracy, prescribing information may change, and healthcare providers should consult the most current manufacturer’s prescribing information before making treatment decisions. Individual patient responses may vary, and therapeutic decisions should be based on clinical judgment and patient-specific factors.
Reviews
Clinical studies demonstrate that Betoptic maintains efficacy in approximately 85% of patients with open-angle glaucoma, with mean intraocular pressure reduction of 6-8 mmHg from baseline. Long-term studies spanning 3-5 years show maintained efficacy without development of tolerance. Patient satisfaction surveys indicate high acceptability, with 78% of patients reporting minimal discomfort upon instillation compared to other glaucoma medications. Ophthalmologists consistently rate Betoptic highly for its cardiovascular safety profile, particularly in patients with mild to moderate respiratory conditions. The solution receives positive evaluations for its ease of administration and minimal impact on daily activities compared to more frequently dosed alternatives.